PHYSIQ vs SHRED vs TITAN: The Three Pepti Blends Compared Ingredient by Ingredient

Every figure is an all-in monthly price covering the medication, physician review, refill management and shipping. There is no separate membership fee. Current pricing always lives on each product page; the table is a guide to which product fits which goal.

Each blend is a 5 mL multi-dose vial. At the standard 0.25 mL dose there are 20 doses per vial, so each dose delivers one twentieth of the vial's contents.

And per injection, at 0.25 mL:

What the overlap means

• Ipamorelin is in all three. It is the ghrelin-receptor half of the growth hormone signal in every blend, at the same 0.5 mg per dose in PHYSIQ and SHRED and 0.6 mg in TITAN.
• PHYSIQ and SHRED share three of four components at identical amounts: AOD-9604, ipamorelin and MOTS-c. The only difference is the GHRH analogue, tesamorelin in PHYSIQ and CJC-1295 in SHRED.
• TITAN is the odd one out. It carries two GHRH analogues, tesamorelin and CJC-1295, plus ipamorelin, which is the same three-secretagogue core as the ASCEND Blend. Its fourth component, BPC-157, is not part of the growth hormone axis at all.
• The ratios are fixed. Each pharmacy formulation sets the proportions, and they cannot be adjusted per component. If a physician wants more of one peptide and none of another, the components are prescribed separately.

The real difference is the fourth and fifth slots, not strength

People often ask which blend is "strongest." That is not a meaningful comparison: no study has measured any of the three, and each delivers a similar total amount of peptide. The useful question is what each blend contains beyond the growth hormone pair. PHYSIQ and SHRED add AOD-9604 and MOTS-c, which is a body-composition rationale resting on mouse work and, for AOD-9604, a negative human trial. TITAN adds BPC-157, a repair rationale resting on animal and cell work, and doubles up on the GHRH signal.

PHYSIQ and SHRED are commonly used alongside semaglutide or tirzepatide. They do a different job: the GLP-1 addresses appetite, and the blend is aimed at the growth hormone axis and muscle fuel handling. No trial has tested any blend with a GLP-1, and no trial shows that a growth hormone secretagogue preserves lean mass during GLP-1 treatment. Growth hormone reduces insulin sensitivity while GLP-1 medications act in the other direction, so glucose is what your physician watches, especially for blends containing tesamorelin. The full list of pairings is in what peptides can you take with tirzepatide.

A blend has no regulatory status of its own; the FDA regulates the bulk substances a pharmacy compounds from. As of the FDA pages checked in September 2026:

None of the six is currently in 503A Category 2, and none is banned. An advisory committee vote is a recommendation, not a decision. All remain legal to prescribe and dispense as compounded medications, and none of the three blends is FDA approved: compounded medications are not FDA approved. Are peptides FDA approved explains the difference between not approved and not legal.

All three are injected under the skin (subcutaneously) into the abdomen or thigh, rotating sites, at 0.25 mL, which is 25 units on a U-100 insulin syringe, five days a week with weekends off. PHYSIQ and TITAN are directed at bedtime, Monday through Friday nights, because the body's largest natural growth hormone pulse happens in the first hours of sleep and the secretagogues are timed to sit alongside it. SHRED is directed once daily Monday through Friday; some prescribers direct a consistent evening time for the same reason. With TITAN, prescribers generally direct the dose away from food, because a rise in glucose and insulin blunts growth hormone release.

You do not need to calculate anything: your physician sets your directions after reviewing your intake, and they are printed on the vial. Twenty doses per vial covers about four weeks, which is why refills run every 28 days, one vial at a time. All three ship refrigerated with ice packs, with sterile syringes and alcohol prep pads, and stay in the fridge between doses. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

Shared by all three. Injection-site redness, mild soreness or occasional bruising, and the effects of raised growth hormone signalling: fluid retention, joint stiffness or aching, tingling in the hands, and headache. These are listed on the approved tesamorelin label at doses well above a blend dose, and are usually described as dose-related. Ipamorelin can raise appetite in some people, and a brief flush after injecting is reported.

PHYSIQ and SHRED. MOTS-c has no human safety data, and AOD-9604's comes from oral and intravenous trials rather than the subcutaneous route, where adverse events were similar between peptide and placebo.

TITAN. The BPC-157 side has no large human safety record. Because it is described around new blood vessel growth, a personal history of cancer and anticoagulant therapy are raised at intake.

For all three, growth hormone reduces insulin sensitivity, so diabetes or impaired glucose tolerance needs discussing first. Stop and contact your physician for any reaction that is severe, spreading, or involves difficulty breathing.

None of the three blends has ever been studied as a blend, in humans or animals, and no study has compared any blend with its components. The evidence is per component and very uneven. Tesamorelin, in PHYSIQ and TITAN, has randomized phase 3 trials on visceral fat in a specific population at higher doses, with weight unchanged. CJC-1295 and ipamorelin have human pharmacology showing growth hormone release, and no outcome trials for body composition, sleep or recovery. AOD-9604's human obesity trials were negative. MOTS-c and BPC-157 rest on animal and cell work. These blends are prescribed on mechanism plus clinical experience; any provider describing them as shown to produce fat loss or muscle gain is overstating what exists.

None of the three can be bought legitimately without a prescription; "research use only" sellers are not accountable for what is in the vial. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A pharmacy compounds it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and dose changes.

Pepti prescribes all three in all 50 states and DC. Step-by-step pages: how to get SHRED prescribed online, how to get tesamorelin prescribed online and how to get CJC-1295 / Ipamorelin prescribed online.